



## **SOMAXON PHARMACEUTICALS, INC. FILES FOR INITIAL PUBLIC OFFERING**

SAN DIEGO, CA – October 7, 2005 - Somaxon Pharmaceuticals, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission relating to an initial public offering of its common stock. All of the shares of common stock are to be offered by the company.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated, acting as sole book-runner and lead manager, J.P. Morgan Securities Inc., acting as co-lead manager, and Piper Jaffray & Co. and Thomas Weisel Partners LLC, acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com), or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, NY 10036, telephone 212-761-6775.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin hydrochloride), is in Phase III clinical trials for the treatment of insomnia.